Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Meng, Li  [Clear All Filters]
2016
Li Q, Zhong Z, Zeng C, Meng L, Li C, Luo Y, Wang H, Li W, Wang J, Cheng F, et al. A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. Oncotarget. 2016.
Wang Y, Shi S, Liu H, Meng L. Hypoxia Enhances Direct Reprogramming of Mouse Fibroblasts to Cardiomyocyte-Like Cells. Cell Reprogram. 2016.
2018
Chen H, Guo S, Xia Y, Yuan L, Lu M, Zhou M, Fang M, Meng L, Xiao Z, Ma J. The Role of Rho-GEF Trio in Regulating Tooth Root Development through the p38 MAPK Pathway. Exp Cell Res. 2018.
2020
Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, Huang M, Meng L, He X, Zhu H, et al. Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy. Cell. 2020.
2021
Dou X, Zheng F, Zhang L, Jin J, Zhang Y, Liu B, Meng L, Zhu X, Lu Z, Jia Y, et al. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study. Ann Hematol. 2021.
Hong L, Yuan L, Xu X, Ma Y, Meng L, Wang J, Zhao N, Wang X, Ma J. Biocompatible Nanotube-Strontium/polydopamine-arginine-glycine-aspartic acid coating on Ti6Al4V enhances osteogenic properties for biomedical applications. Microsc Res Tech. 2021.
Cao Y, Yi X, Wang N, Wang GX, Huang L, Hong Z, Meng L, Zhou X, Wang J, Hao X, et al. CD19/CD22 CAR T cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas: Combined CAR T Cell Therapy and Transplantation. Transplant Cell Ther. 2021.
2023
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Chen S, Meng L, Wang S, Xu Y, Chen W, Wei J. Effect assessment of a type of xeno-free and serum-free human adipose-derived mesenchymal stem cells culture medium by proliferation and differentiation capacities. Cytotechnology. 2023;75(5):403-420.
Meng L, Zhao P, Jiang Y, You J, Xu Z, Yu K, Boccaccini AR, Ma J, Zheng K. Extracellular and intracellular effects of bioactive glass nanoparticles on osteogenic differentiation of bone marrow mesenchymal stem cells and bone regeneration in zebrafish osteoporosis model. Acta Biomater. 2023.
Yang S, Zhang X, Gale RPeter, Du X, Chen C-Y, Weng J-Y, Huang J, Li F, Zeng Y, Xiao Z, et al. Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol. 2023.
Lv Q, Cao Y, Wang J, Meng L, Wang GX. Metagenomic Next-generation Sequencing May be a Tool for Timely Diagnosis of Seronegative and Primary Toxoplasma Infection After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review. Pediatr Infect Dis J. 2023.
Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.
2024
Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, et al. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024.
Peng Y, Huang J, Yin J, Meng F, Cao Y, Huang L, Li D, Zhang Y, Zhang D, Meng L, et al. Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Hematol. 2024.